WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206616

CAS#: 1365267-27-1

Description: X-376 is an ALK inhibitor and potentially useful in non-small cell lung cancer.

Price and Availability




X-376 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 206616
Name: X-376
CAS#: 1365267-27-1
Chemical Formula: C25H25Cl2FN6O3
Exact Mass: 546.1349
Molecular Weight: 547.4124
Elemental Analysis: C, 54.85; H, 4.60; Cl, 12.95; F, 3.47; N, 15.35; O, 8.77

Synonym: X-376; X 376; X376

IUPAC/Chemical Name: 6-Amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-N-[4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]-3-pyridazinecarboxamide


InChi Code: InChI=1S/C25H25Cl2FN6O3/c1-14(21-17(26)7-8-18(28)22(21)27)37-20-13-19(31-32-23(20)29)24(35)30-16-5-3-15(4-6-16)25(36)34-11-9-33(2)10-12-34/h3-8,13-14H,9-12H2,1-2H3,(H2,29,32)(H,30,35)/t14-/m1/s1

SMILES Code: O=C(C1=NN=C(N)C(O[C@@H](C2=C(Cl)C=CC(F)=C2Cl)C)=C1)NC3=CC=C(C(N4CCN(C)CC4)=O)C=C3

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Sullivan I, Planchard D. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol. 2016 Jan;8(1):32-47. doi: 10.1177/1758834015617355. Review. PubMed PMID: 26753004; PubMed Central PMCID: PMC4699265.

2: Qiu W, Yuchi M, Ding M, Tessier D, Fenster A. Needle segmentation using 3D Hough transform in 3D TRUS guided prostate transperineal therapy. Med Phys. 2013 Apr;40(4):042902. doi: 10.1118/1.4795337. PubMed PMID: 23556924.

3: Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C, Pao W. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res. 2011 Jul 15;71(14):4920-31. doi: 10.1158/0008-5472.CAN-10-3879. Epub 2011 May 25. PubMed PMID: 21613408; PubMed Central PMCID: PMC3138877.

4: Byrne PV. Human myeloid cells possessing high-affinity receptors for granulocyte-macrophage colony stimulating factor. Leuk Res. 1989;13(2):117-26. PubMed PMID: 2538682.